摘要
目的探讨阿立哌唑联合氨磺必利治疗方案对首发精神分裂症患者的临床疗效及安全性。方法选取2015年6月至2016年12月我院收治的76例临床确诊的首发精神分裂症患者,依据用药方案分为对照组(38例)和观察组(38例)。对照组应用氨磺必利,观察组在常规氨磺必利基础上联合应用阿立哌唑,两组均治疗6周。检测治疗前和治疗6周后阳性与阴性症状量表(PANSS)评分,应用药物副作用量表评定治疗安全性。结果治疗6周后,对照组和观察组患者PANSS评分值(分别为66.37±6.87和48.35±6.04)均较治疗前(分别为109.67±8.92和112.15±9.14)显著下降(P<0.01);且治疗后观察组PANSS评分显著低于对照组,差异具有统计学意义(P<0.01)。观察组治疗有效率(97.4%)显著高于对照组(81.6%),差异具有统计学意义(P<0.05)。用药安全性分析结果提示,两组患者不良反应对比差异无统计学意义(P>0.05)。结论联合应用阿立哌唑和氨磺必利治疗首发精神分裂症疗效显著,且药物不良反应少,具有较好的临床应用价值。
Objective To investigate the clinical efficacy and safety of aripiprazole combined with amisulpride in the treatment of first-episode schizophrenia.Methods Totally 76 cases with the clinical diagnosis of first-episode schizophrenia in our hospital from June 2015 to December 2016 were divided into control group(n=38)and observation group(n=38).The control group was treated with amisulpride,and the observation group was treated with aripiprazole on the basis of routine amisulpride.Both groups were treated for 6 weeks.The positive and negative symptom scale(PANSS)scores were measured before and at 6 weeks after treatment,and the safety of treatment was assessed by the drug side effects scale.Results After 6 weeks of treatment,the PANSS scores of control group and observation group(66.37±6.87 and 48.35±6.04 respectively)were significantly lower than those before treatment(109.67±8.92 and 112.15±9.14 respectively)(P<0.01),and the PANSS scores of observation group were significantly lower than those of control group after treatment(P<0.01).The effective rate of treatment in observation group(97.4%)was significantly higher than that in control group(81.6%),and the difference was statistically significant(P<0.05).The results of drug safety analysis showed that there was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion The combination wse of aripiprazole and amsopride is effective in the treatment of first-episode schizophrenia with few adverse drug reactions,so it has certain clinical application value.
作者
赵成清
王会秋
何俊鹏
李群
ZHAO Cheng-qing;WANG Hui-qiu;HE Jun-peng;LI Qun(First Department of Psychology,Shenyang Anning Hospital,Shenyang 110001,China;Department of Rehabilitation,Shenyang Anning Hospital,Shenyang 110001,China)
出处
《实用药物与临床》
CAS
2019年第3期286-288,共3页
Practical Pharmacy and Clinical Remedies
基金
2016年沈阳市科学技术计划(人口与健康科技攻关专项)F16-206-9-42
